Halts development of AIDS drug, soluble T4, manufactured by Invitron, due to production scale-up problems. SmithKline said it will pursue second generation products "which work by the same mechanism but which can be produced in substantial quantities." Development of soluble T4, also known as CD4, provided 73% of Invitron's revenues in the first 9 months of 1989.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.